Breaking News Instant updates and real-time market news.

DMPI

DelMar Pharmaceuticals

$3.94

2.295 (139.51%)

08:49
06/03/19
06/03
08:49
06/03/19
08:49

DelMar Pharmaceuticals provides update on VAL-083 studies

DelMar Pharmaceuticals presented clinical updates from the company's ongoing first- and second-line trials in patients with MGMT-unmethylated glioblastoma multiforme at a key opinion leader forum focused on brain tumors and the role of VAL-083 to address the unmet medical need in GBM during the 2019 American Society of Clinical Oncology annual meeting in Chicago, IL. At the KOL forum, the company provided an update on the ongoing Phase 1/2 clinical study investigating the front line treatment of VAL-083 with radiation therapy in newly diagnosed MGMT-unmethylated GBM. This trial is being conducted at the Sun Yat-sen University Cancer Center in Guangzhou, China in collaboration with Guangxi Wuzhou Pharmaceutical Company. The trial is designed to enroll up to 30 patients to determine if first-line therapy with VAL-083 treatment, in lieu of first-line temozolomide, improves progression free survival. As of May 17, eighteen patients have been enrolled in the trial. Of these patients, fifteen have received their post-cycle 3 MRI and investigator assessment, and ten have received their post-cycle 7 MRI and investigator assessment. Two patients have not been on the study long enough to reach their first assessment, and one patient died before their first assessment. Assessments are based on the trial investigator's clinical and radiologic assessment, according to the Response Assessment in NeuroOncology (RANO) criteria. For the fifteen patients who have received at least one assessment, eight patients were assessed with a best response of "Complete Response" (8/15, 53.3% CR) and seven patients were assessed with a best response of "Stable Disease" (7/15, 46.7% SD). Fourteen of the eighteen patients were still alive at the data cut-off date. The company also provided an update on the ongoing second-line Phase 2 clinical study of VAL-083 in patients with MGMT-unmethylated, Bevacizumab-naive recurrent GBM. This study is being conducted in collaboration with The University of Texas MD Anderson Cancer Center. This biomarker-driven trial has been amended to enroll up to 83 patients (35 with a starting dose of 40 mg/m2; 48 with a starting dose of 30 mg/m2) to determine the potential of VAL-083 treatment to improve overall survival compared to historical reference control of 7.2 months with lomustine. As of May 5, 51 patients have been enrolled, 35 patients at a starting dose of 40 mg/m, and 16 patients at a starting dose of 30 mg/m. For the 47 patients who have been on study long enough to be assessed at the post-cycle 2 MRI: 9/35 (25.7%) patients initially receiving 40 mg/m exhibited "Stable Disease" per investigator assessment at the end of cycle 2; 4/12 (33.3%) patients initially receiving 30 mg/m2 exhibited "Stable Disease" per investigator assessment at the end of cycle 2. Consistent with prior studies, myelosuppression is the most common adverse event in both ongoing clinical trials.

TODAY'S FREE FLY STORIES

UNH

UnitedHealth

$233.50

13.18 (5.98%)

, ANTM

Anthem

$244.77

10.04 (4.28%)

09:55
10/15/19
10/15
09:55
10/15/19
09:55
Options
Early notable gainers among liquid option names on October 15th »

Notable gainers among…

UNH

UnitedHealth

$233.50

13.18 (5.98%)

ANTM

Anthem

$244.77

10.04 (4.28%)

CI

Cigna

$157.49

5.875 (3.87%)

SCHW

Charles Schwab

$38.63

0.89 (2.36%)

NVDA

Nvidia

$192.32

5.81 (3.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 31

    Oct

  • 20

    Nov

EMR

Emerson

$66.89

-0.32 (-0.48%)

09:54
10/15/19
10/15
09:54
10/15/19
09:54
Hot Stocks
D. E. Shaw sees 50% upside in Emerson shares, calls for cost cuts and split »

D. E. Shaw Group, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

JNJ

Johnson & Johnson

$132.66

1.99 (1.52%)

09:53
10/15/19
10/15
09:53
10/15/19
09:53
Hot Stocks
Breaking Hot Stocks news story on Johnson & Johnson »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

EMR

Emerson

$67.03

-0.18 (-0.27%)

09:51
10/15/19
10/15
09:51
10/15/19
09:51
Hot Stocks
Breaking Hot Stocks news story on Emerson »

D.E. Shaw calls for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

TNDM

TNDM

, ABT

Abbott

$81.63

1.82 (2.28%)

09:50
10/15/19
10/15
09:50
10/15/19
09:50
Recommendations
TNDM, Abbott, DexCom, Insulet analyst commentary  »

Abbott partnership a…

TNDM

TNDM

ABT

Abbott

$81.63

1.82 (2.28%)

DXCM

DexCom

$153.56

-6.64 (-4.14%)

PODD

Insulet

$154.02

1.72 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 13

    Nov

  • 14

    Nov

AMBA

Ambarella

$56.30

3.19 (6.01%)

09:50
10/15/19
10/15
09:50
10/15/19
09:50
Recommendations
Ambarella analyst commentary  »

KeyBanc boosts Ambarella…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

09:50
10/15/19
10/15
09:50
10/15/19
09:50
General news
IMF's global growth outlooks were trimmed »

IMF's global growth…

NR

Newpark Resources

$6.77

-0.155 (-2.24%)

09:47
10/15/19
10/15
09:47
10/15/19
09:47
Hot Stocks
Newpark Resources falls -5.3% »

Newpark Resources is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

MTW

Manitowoc

$10.71

-0.68 (-5.97%)

09:47
10/15/19
10/15
09:47
10/15/19
09:47
Hot Stocks
Manitowoc falls -5.9% »

Manitowoc is down -5.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$40.25

-6 (-12.97%)

09:47
10/15/19
10/15
09:47
10/15/19
09:47
Hot Stocks
PagSeguro Digital falls -13.7% »

PagSeguro Digital is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

  • 17

    Dec

  • 17

    Oct

UNH

UnitedHealth

$233.30

12.98 (5.89%)

09:47
10/15/19
10/15
09:47
10/15/19
09:47
Hot Stocks
UnitedHealth rises 5.7% »

UnitedHealth is up 5.7%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

FRC

First Republic

$103.44

6.08 (6.24%)

09:47
10/15/19
10/15
09:47
10/15/19
09:47
Hot Stocks
First Republic rises 6.0% »

First Republic is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

APHA

Aphria

$5.39

1.06 (24.48%)

09:47
10/15/19
10/15
09:47
10/15/19
09:47
Hot Stocks
Aphria rises 21.8% »

Aphria is up 21.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 12

    Nov

TBPH

Theravance Biopharma

$17.25

(0.00%)

09:45
10/15/19
10/15
09:45
10/15/19
09:45
Syndicate
Theravance Biopharma 5.7M share Block Trade priced at $17.50 »

Woodford Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BYSI

BeyondSpring

$18.08

(0.00%)

09:44
10/15/19
10/15
09:44
10/15/19
09:44
Syndicate
Breaking Syndicate news story on BeyondSpring »

BeyondSpring files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

EMR

Emerson

$67.21

(0.00%)

09:43
10/15/19
10/15
09:43
10/15/19
09:43
Periodicals
D.E. Shaw report calling for Emerson split coming today, CNBC reports »

D.E. Shaw has over a 1%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

STLD

Steel Dynamics

$29.64

(0.00%)

, IGT

International Game

$14.02

(0.00%)

09:40
10/15/19
10/15
09:40
10/15/19
09:40
Options
Unusually active option classes on open October 15th »

Unusual total active…

STLD

Steel Dynamics

$29.64

(0.00%)

IGT

International Game

$14.02

(0.00%)

JPM

JPMorgan

$116.39

(0.00%)

UNH

UnitedHealth

$220.32

(0.00%)

GS

Goldman Sachs

$205.81

(0.00%)

NVDA

Nvidia

$186.51

(0.00%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.83

(0.00%)

C

Citi

$70.28

(0.00%)

WLL

Whiting Petroleum

$7.26

(0.00%)

SCHW

Charles Schwab

$37.74

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 17

    Oct

  • 18

    Oct

  • 27

    Oct

  • 04

    Nov

  • 06

    Nov

  • 12

    Nov

  • 20

    Nov

CPIX

Cumberland

$5.59

-0.05 (-0.89%)

09:38
10/15/19
10/15
09:38
10/15/19
09:38
Hot Stocks
Cumberland: Study shows Vibativ superiority in some bacterial pneumonia patients »

Cumberland…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMR

Emerson

$67.21

0.16 (0.24%)

09:37
10/15/19
10/15
09:37
10/15/19
09:37
Periodicals
Breaking Periodicals news story on Emerson »

D.E. Shaw to call for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

IAC

IAC

$226.69

-0.5 (-0.22%)

, MTCH

Match Group

$74.00

-0.12 (-0.16%)

09:34
10/15/19
10/15
09:34
10/15/19
09:34
Conference/Events
Cowen US internet/media analyst to hold analyst/industry conference call »

U.S. Internet & Media…

IAC

IAC

$226.69

-0.5 (-0.22%)

MTCH

Match Group

$74.00

-0.12 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.28

-0.14 (-3.17%)

09:31
10/15/19
10/15
09:31
10/15/19
09:31
Downgrade
Encana rating change  »

Encana downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

WLL

Whiting Petroleum

09:31
10/15/19
10/15
09:31
10/15/19
09:31
Downgrade
Whiting Petroleum rating change  »

Whiting Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

OAS

Oasis Petroleum

$3.11

-0.135 (-4.17%)

09:31
10/15/19
10/15
09:31
10/15/19
09:31
Downgrade
Oasis Petroleum rating change  »

Oasis Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBL

Noble Energy

$20.44

-0.15 (-0.73%)

09:31
10/15/19
10/15
09:31
10/15/19
09:31
Upgrade
Noble Energy rating change  »

Noble Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

PH

Parker-Hannifin

$178.45

-1.25 (-0.70%)

09:30
10/15/19
10/15
09:30
10/15/19
09:30
Recommendations
Parker-Hannifin analyst commentary  »

Parker-Hannifin sales,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.